Department of Paediatrics, Willem Alexander Children's Hospital, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands.
Eur J Pediatr. 2021 Aug;180(8):2485-2492. doi: 10.1007/s00431-021-04068-1. Epub 2021 Apr 15.
The aim of this study was (1) to prospectively evaluate the nationwide implementation of the ESPGHAN-guidelines for the diagnosis of celiac disease (CD), (2) to investigate the incidence and clinical presentation of diagnosed childhood CD (0-14 years) in the Netherlands, and (3) to compare the findings with national survey data from 1975 to 1990 and 1993 to 2000 using the same approach. From 2010 to 2013, all practicing paediatricians were invited to report new celiac diagnoses to the Dutch Pediatric Surveillance Unit. Data were collected via questionnaires. A total of 1107 children with newly diagnosed CD were reported (mean age, 5.8 years; range, 10 months-14.9 years; 60.5% female). After the introduction of the non-biopsy approach in 2012, 75% of the diagnoses were made according to the guideline with a significant decrease of 46.3% in biopsies. The use of EMA and HLA-typing significantly increased with 25.8% and 62.1%, respectively. The overall incidence rate of childhood CD was 8.8-fold higher than in 1975-1990 and 2.0-fold higher than in 1993-2000. During the study period, the prevalence of diagnosed CD was 0.14%, far below 0.7% of CD identified via screening in the general Dutch paediatric population. Clinical presentation has shifted towards less severe and extra-intestinal symptoms.Conclusion: ESPGHAN guidelines for CD diagnosis in children were effectively and rapidly implemented in the Netherlands. Incidence of diagnosed CD among children is still significantly rising with a continuous changing clinical presentation. Despite the increasing incidence of diagnoses, significant underdiagnosis still remains. What is Known: • Since 2000 the incidence of diagnosed childhood CD in the Netherlands has shown a steady rise. • The rise in incidence has been accompanied by a changing clinical presentation at diagnosis. What is New: • The ESPGHAN guidelines 2012 for CD diagnosis were effectively and rapidly implemented in the Netherlands. • The incidence of diagnosed childhood CD in the Netherlands has continued to rise significantly during the reported period.
(1) 前瞻性评估 ESPGHAN 关于乳糜泻 (CD) 诊断指南在全国范围内的实施情况;(2) 调查荷兰确诊的儿童 CD(0-14 岁)的发病率和临床表现;(3) 并使用相同方法将这些发现与 1975 年至 1990 年和 1993 年至 2000 年的全国调查数据进行比较。2010 年至 2013 年,所有执业儿科医生均被邀请向荷兰儿科监测单位报告新的乳糜泻诊断。数据通过问卷调查收集。共报告了 1107 例新诊断的 CD 儿童(平均年龄为 5.8 岁;范围为 10 个月至 14.9 岁;60.5%为女性)。2012 年引入非活检方法后,根据指南进行的诊断占 75%,活检数量显著减少 46.3%。EMA 和 HLA 分型的使用分别显著增加了 25.8%和 62.1%。儿童 CD 的总发病率比 1975-1990 年高 8.8 倍,比 1993-2000 年高 2.0 倍。在研究期间,确诊 CD 的患病率为 0.14%,远低于荷兰普通儿科人群中通过筛查发现的 0.7%。临床表现已向较轻的和肠外症状转变。结论:荷兰儿童 CD 诊断的 ESPGHAN 指南得到了有效且迅速的实施。儿童确诊 CD 的发病率仍在持续上升,且临床表现不断变化。尽管诊断率不断上升,但仍存在显著的漏诊情况。已知情况:• 自 2000 年以来,荷兰确诊儿童 CD 的发病率一直呈稳步上升趋势。• 发病率的上升伴随着诊断时临床表现的变化。新发现:• ESPGHAN 2012 年 CD 诊断指南在荷兰得到了有效且迅速的实施。• 在报告期内,荷兰确诊儿童 CD 的发病率继续显著上升。